Glaukos Beats with $211M Q3 Sales, Raises 2026 Guidance to $775-785M and Sets $1B 2027 Target
GKOS has more than doubled off its 52-week low of $73.16 on elevated volume (2.0× avg).
Summary
Glaukos posted record Q3 2026 sales of $211.0 million (+58% year-over-year) and raised 2026 guidance to $775-785 million while introducing a $1 billion preliminary 2027 target.
Key Events · Earnings and Guidance · GKOS
-
Record Q3 Sales of $211.0M
Net sales rose 58% year-over-year on a reported and constant currency basis from $133.5 million, with U.S. Glaucoma at $118.6 million (+47%) and Corneal Health at $59.0 million (+154%).
-
2026 Guidance Raised Sharply
Full-year 2026 net sales guidance lifted to $775-785 million from the prior $680-700 million range.
-
$1 Billion 2027 Target Introduced
Preliminary 2027 net sales guidance set at $1 billion, implying roughly 28% growth over the top of the 2026 range.
-
Profitability Inflection
GAAP net income of $2.0 million ($0.03 per diluted share) versus a $16.2 million loss a year ago; non-GAAP net income of $28.5 million ($0.47 per diluted share) versus a $9.2 million non-GAAP loss.
Analysis · GKOS · Industrial Applications And Services
Record quarterly sales of $211.0 million, up 58% year-over-year, and a swing to GAAP net income of $2.0 million from a $16.2 million loss a year ago mark the quarter. More important for the thesis, management raised full-year 2026 revenue guidance to $775-785 million from $680-700 million and introduced a preliminary 2027 target of $1 billion — a step-change in the growth outlook driven by iDose TR and the Epioxa launch. With $339.8 million in cash and no debt at quarter-end, the growth is being funded internally rather than through dilution.
How filings like this one have moved
In the 30 days to Oct 29, 2026, 39% of the 991 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GKOS was trading at $196.05 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $10.7B. The 52-week trading range was $73.16 to $191.62. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.